Lifetime cancer potency of alfatoxin was assessed based on the Yehet al.study from China in which both aflatoxin exposure and hepatitis B prevalence were measured. This study provides the best available information for estimating the carcinogenic risk posed by aflatoxin to the U.S. population. Cancer potency of aflatoxin was estimated using a biologically motivated risk assessment model. The best estimate of aflatoxin potency was 9 (mg/kg/day)−1for individuals negative for hepatitis B and 230 (mg/kg/day)−1for individuals positive for hepatiti
展开▼
